Shanda Blackmon named director of Baylor’s Lung Institute

Nuvalent announces positive topline pivotal data from ALKOVE-1 trial of neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC

Nuvalent, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 phase I/II clinical trial.

November 21, 2025

Drugs & Targets

FDA approves Hyrnuo for HER2-mutated NSCLC

FDA has approved Hyrnuo (sevabertinib), an oral, reversible, tyrosine kinase inhibitor, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.

November 21, 2025

City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure

As we mark Lung Cancer Awareness Month, it is a time to acknowledge that screening and prevention are vital, and equally crucial is ensuring that patients have access to state-of-the-art care and research. Herein, I spotlight some of the transformative work underway at City of Hope.

November 07, 2025

Vol.51 No.41

By Ravi Salgia

Cancer Policy

Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients

FDA announced six additional awardees under the Commissioner’s National Priority Voucher pilot program, which aims to accelerate review time for applications that are deemed to be advancing U.S. “national priorities” (The Cancer Letter, Oct. 24, June 20, 2025).

Some p53 mutations could help fight cancer, Baylor study finds

The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading to cancer. But when p53 mutates, it can flip from protector to promoter of cancer.

November 07, 2025

Vol.51 No.41

In Brief

Montefiore Einstein Comprehensive Cancer Center’s lung cancer team earns international recognition

Montefiore Einstein Comprehensive Cancer Center announced that its lung cancer team has been recognized by the International Association for the Study of Lung Cancer for delivering outstanding care. The announcement was made during the IASLC annual meeting in Barcelona.

October 03, 2025

Vol.51 No.36

Shanda Blackmon named director of Baylor’s Lung Institute

YOU MAY BE INTERESTED IN

Nuvalent announces positive topline pivotal data from ALKOVE-1 trial of neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC

FDA approves Hyrnuo for HER2-mutated NSCLC

City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure

Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients

Some p53 mutations could help fight cancer, Baylor study finds

Montefiore Einstein Comprehensive Cancer Center’s lung cancer team earns international recognition

Renew today!

Subscriber content

Never miss an issue!

Login